Patents by Inventor HongYing Yun

HongYing Yun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416238
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X, Cy and R1 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230391764
    Abstract: The present invention provides novel compounds having the general formula: wherein R1, R2, L, and A are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 23, 2023
    Publication date: December 7, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230331715
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Jianping WANG, Hongying YUN, Xiufang ZHENG
  • Publication number: 20230312491
    Abstract: The present invention provides novel compounds having the general formula (I): wherein R1 to R3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 5, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286969
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286927
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286930
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286929
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X1, X2 and R1 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286968
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, L1, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230278997
    Abstract: The present invention provides novel compounds having the general formula (I): wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 7, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jianping WANG, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20220064128
    Abstract: The present invention relates to compounds of formula (I), wherein R1-R5 and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Hongying Yun, Weixing Zhang, Kun Miao, Jianguo Chen, Yao Wu
  • Patent number: 11242345
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 11220502
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: January 11, 2022
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Chungen Liang, Jianping Wang, Hongying Yun, Kun Miao
  • Publication number: 20210371432
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: FABIAN DEY, HONG SHEN, HONGTAO XU, HONGYING YUN, GE ZOU, WEI ZHU
  • Patent number: 11180525
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: November 23, 2021
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Dongdong Chen, Song Feng, Lu Gao, Chao Li, Baoxia Wang, Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 11046671
    Abstract: This invention relates to new benzazepine carboxamide compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 29, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Lisha Wang, Hongying Yun, Weixing Zhang, Zhiwei Zhang, Wei Zhu
  • Patent number: 10975098
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Xiufang Zheng
  • Publication number: 20200385387
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 10, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20200369664
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen LIANG, Jianping WANG, Hongying YUN, Kun MIAO
  • Patent number: RE49481
    Abstract: A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: April 4, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Li Chen, Lichun Feng, Song Feng, Lu Gao, Tao Guo, Mengwei Huang, Chungen Liang, Yongfu Liu, Lisha Wang, Jason Christopher Wong, Jim Zhen Wu, Xihan Wu, Hongying Yun, Xiufang Zheng